Introduction
Effective blood pressure control in essential hypertension may be achieved through blockade of the renin-angiotensin system (RAS). Angiotensin-converting enzyme (ACE) inhibitors effectively block the cascade by suppressing angiotensin II levels through inhibition of the converting enzyme, and have played a major role in the management of hypertension during the past decade. 1, 2 However, inhibition of the converting enzyme has effects beyond the RAS and results in well recognised sideeffects associated with this class of agents including cough and angioneurotic oedema. These side-effects are thought to be due to the accumulation of other substrates of the converting enzyme such as bradykinin and substance P. 3, 4 Selective inhibition of the RAS at a more distal baseline in trough MSuDBP, indicated a positive dose response. Responder rates were 16%, 24%, 33%, 46%, 54% for placebo, valsartan 10 mg, 40 mg, 80 mg, 160 mg respectively, which also indicated a positive dose response in the dose range of 10 mg to 160 mg. Greater than 50% of the antihypertensive effect measured at peak persisted at trough for each of the four active treatment groups, confirming efficacy over a 24-h period. No dose-related adverse experiences were observed, with overall incidence (regardless of relationship to trial medication) of 44% with placebo and 44%, 36%, 22%, 21% for valsartan 10 mg, 40 mg, 80 mg, 160 mg respectively. The most common adverse experience reported was headache which occurred most frequently with placebo (12%). No trial drug-related cough was observed. Treatment with valsartan did not produce clinically significant orthostatic changes in diastolic or systolic blood pressure. One case of symptomatic orthostatic hypotension was observed on placebo. Conclusions: The results of this trial show valsartan to effectively lower blood pressure in patients with mildto-moderate hypertension, and demonstrate that the reduction in blood pressure increases with increasing dose levels.
level would be anticipated to result in effective antihypertensive agents devoid of these unwanted effects. Angiotensin II antagonists, also known as angiotensin II receptor blockers, have a novel mechanism of action and have been reported to effectively lower blood pressure without cough as a side effect. [5] [6] [7] [8] These agents effectively block the RAS by competitive antagonism of the action of angiotensin II at its cellular receptor site. 5, 6, 7, 9 The AT 1 cellular receptor site appears to mediate most of the known actions of angiotensin II, although a second receptor site exists, AT 2 , 10 which appears to play an important role in apoptosis 11 and inhibition of cell growth and fibrillar collagen metabolism. 12 Valsartan is a new orally active angiotensin II antagonist which inhibits the RAS by selectively preventing the interaction of angiotensin II at its AT 1 cellular receptor site 9, 13 Previous Phase I trials with valsartan have shown it to be well tolerated in single doses ranging from 10 to 400 mg once daily. 14 Adverse experiences reported in these trials were of mild-to-moderate intensity, generally self-limiting and judged unlikely to be related to valsartan. The most common adverse experience observed was headache.
The current placebo-controlled, dose-ranging study was undertaken to assess the efficacy, tolerability and safety of valsartan 10 mg, 40 mg, 80 mg and 160 mg once daily, and to explore the doseresponse relationship of valsartan in the reduction of blood pressure over this dose range. The doses selected in this trial covered the potential therapeutic range for valsartan based on previous trials.
Materials and methods

Patients
Male and post-menopausal or surgically sterile female outpatients, aged 18-70 years, diagnosed with uncomplicated mild-to-moderate essential hypertension, defined as mean supine diastolic blood pressure (MSuDBP) у95 mm Hg and р115 mm Hg, were eligible to participate in the trial. Patients were required to have less than ±5 mm Hg variability in MSuDBP and no significant orthostatic blood pressure changes during a 4-week placebo run-in period.
The most important exclusion criteria were a history of heart failure within the preceding 6 months; second or third degree heart block, concomitant angina pectoris, or clinically relevant arrhythmias; clinically significant valvular heart disease; hypertensive retinopathy (Grade III or IV); history of hypertensive encephalopathy or cerebrovascular accident; confirmed evidence of hepatic disease and/or renal impairment; or insulin-dependent diabetes mellitus.
All patients gave written consent to participate in the study which was approved by the relevant Institutional Review Board. The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice requirements.
Study design
This was a multicentre (five centre), double-blind, randomised, placebo-controlled, fixed dose, parallel design trial of 4 weeks duration. After the placebo run-in period, patients were randomised in equal numbers to receive either valsartan 10 mg, valsartan 40 mg, valsartan 80 mg, valsartan 160 mg, or placebo once daily (OD) for 4 weeks.
All trial drugs were presented as identical capsules to be taken once a day in the morning. The use of concomitant medications that could interfere with the evaluation of efficacy or safety were not allowed throughout the duration of the trial.
Patients were assessed at baseline and at 2 and 4 weeks post treatment. On visit days, blood samples, supine and standing blood pressure and pulse measurement were taken prior to that day's intake of study medication (trough measurement). Patients then remained in the office for a 6-h observation period during which supine and standing blood pressure and pulse were measured at 2, 4 and 6 h postdosing. In addition, plasma renin activity, angiotensin II, aldosterone and valsartan plasma levels were measured pre-dose and at 2, 4 and 6 h post-dose.
The primary efficacy variable was the change from baseline in trough MSuDBP after 4 weeks of treatment. Secondary variables included change from baseline in mean supine systolic blood pressure (MSuSBP), and trough/peak ratio, defined as the ratio of the difference in least squares MSuDBP of valsartan pre-dose to valsartan post-dose, after subtraction of the placebo effect. Responder rates were defined as MSuDBP Ͻ90 mm Hg or a у10 mm Hg decrease compared to baseline.
The main criterion for tolerability and safety was the reporting of adverse experiences, orthostatic changes in blood pressure and symptomatic orthostatic hypotension (defined as a postural decrease of blood pressure from supine to standing after 2 min у20 mm Hg in SBP and/or a decrease у10 mm Hg in DBP accompanied by symptoms of cerebral hypoperfusion).
Statistical methodology
The originally planned sample size of 100 evaluable patients was chosen to assess whether a dose response exists in the dose range of 10 mg to 160 mg and was not based on a statistical calculation for pairwise comparisons between doses. Comparability among treatment groups for baseline demographics was examined using the Mantel-Haenszel chisquare test and the F-test.
For each efficacy variable, an analysis of covariance was performed both as a within-treatment analysis (post treatment end-point compared to baseline) and a between-treatment analysis (compared to placebo) of covariance with treatment group and trial centres as factors and baseline as covariate.
A polynomial regression analysis was performed to investigate the dose-response relationship for change from baseline in trough MSuDBP at endpoint. The goodness of fit for a quadratic response curve was examined by a lack-of-fit test. The standardised unit for valsartan dose was used in the regression analysis.
Two patient datasets were analysed, the intent-totreat dataset including all randomised patients with a baseline measurement and at least one post-baseline measurement carried forward in case of premature discontinuation, and the Week 4 patient dataset consisting of all randomised patients with both baseline and Week 4 measurements. All patients were included in the safety analysis, which was descriptive.
The trough/peak ratios for all valsartan treatment groups were assessed for change from baseline in diastolic blood pressure by means of a two-way repeated measures analysis of covariance, using all patients with available measurements at all three post-dose time points. The trough/peak ratio estimates were calculated based on the placebo-subtracted least squares means at trough and peak. Three post-dose time points (hours 2, 4, and 6) were included to investigate a peak effect.
The pharmacokinetic assessment of plasma concentration and its relationship with pharmacodynamic effect (diastolic blood pressure reduction) was explored by summary statistics. All patients with both plasma concentration and diastolic blood pressure were included in this descriptive assessment.
Results
Patients
A total of 122 patients were randomised to receive treatment, with 114 completing the trial as planned. The intention-to-treat (primary) analysis included 120 patients as two randomised patients were prematurely discontinued from the trial without a post-baseline blood pressure measurement. Of the patients who discontinued prematurely these were due to either unsatisfactory therapeutic response (three patients), adverse experiences (two patients), or 'other' reasons (three patients). Table 1 shows the patient demographics and baseline characteristics. A significant difference between the treatment groups was found for sex (P = 0.041), height (P = 0.014) and significant past medical history/concomitant diagnosis (P = 0.011). Additional analyses were performed by incorporation of these variables into an analysis of covariance model for the primary efficacy variable. Similar least squares means were obtained indicating there was no major impact on the conclusion due to these imbalances. In all groups the majority of patients had significant medical histories or concomitant diagnoses (range 76-100%). No other significant baseline demographic differences were detected among the five treatment groups.
Efficacy
Results for the intention-to-treat dataset were similar to those for the Week 4 dataset; therefore, only the intention-to-treat data are reported. Mean supine diastolic blood pressure: Although the pre-specified analysis of covariance was performed, an analysis of covariance using a reduced model (deleting treatment-by-centre interaction from the original model) was also performed for change from baseline in diastolic blood pressure. The analysis of covariance using the reduced model was added due to the statistical consideration of relatively high variation in the distribution of sample sizes among the five study centres (ranged from 1-2 patients to 4 -5 patients per group). Both analyses produced relatively comparable least squares means and treatment differences. In fact, the prespecified analysis results were slightly more favourable to valsartan (ie, a slightly greater placebo-subtracted mean reduction in diastolic blood pressure). For simplicity, the more conservative (least favourable) analysis results using the reduced model are reported in the manuscript. A significant reduction in trough MSuDBP from baseline was observed in all treatment groups at 4-week end-point (P Ͻ 0.001), with greater changes observed for increasing doses of valsartan (least squares mean change from baseline: placebo, −4.4 mm Hg; valsartan 10 mg, −4.9 mm Hg; valsartan 40 mg, −6.5 mm Hg; valsartan 80 mg, −8.2 mm Hg; valsartan 160 mg, −9.1 mm Hg) (Figure 1 ). The global test to assess the efficacy of four doses of valsartan vs placebo was statistically significant (P Ͻ 0.05) with the Dunnett multiple comparison procedure applied. The sample sizes were relatively small so the power at the planning stage was somewhat low to detect statistical significance between individual doses of valsartan and placebo. Nevertheless, both valsartan 80 mg and 160 mg reached statistical significance at the nominal level of 0.05 (ie, no adjustment). The results of the pairwise comparisons to placebo are given in Table 2 .
The regression analysis for the assessment of dose The lack-of-fit test result and predicted dose responses were precisely identical whether the standardised unit or the actual dose is used. The lack-offit test result was highly non-significant (P = 0.955) indicating that the goodness of fit was strong. The estimated slope of the linear term was highly significant (P = 0.008), indicating that there was a positive dose response: an increase in mean reduction in blood pressure with increasing doses (Figure 2) . The goodness of fit of the model was also confirmed by the comparison between the predicted responses and the observed values in diastolic blood pressure reduction in Table 3 . Furthermore, the observed raw mean reductions in all dose groups in Table 3 also descriptively indicated a positive dose response.
For robustness purposes, both Emax model and log-linear model were subsequently assessed. The predicted mean diastolic blood pressure reductions were all comparable among the three models, indicating that the conclusion with a positive dose response for valsartan was evident. For simplicity, only the results based on the pre-specified model are presented in this manuscript.
Mean supine systolic blood pressure:
For the analysis of MSuSBP, the original and modified covariance model with/without the treatment-bycentre interaction term was used. As the results of both models were similar, only those calculated from the original model are reported.
All treatments decreased trough MSuSBP compared to baseline (least squares mean change from baseline: placebo, −1.32 mm Hg; valsartan 10 mg, −3.64 mm Hg; valsartan 40 mg, −6.97 mm Hg; valsartan 80 mg, −11.07 mm Hg; valsartan 160 mg, −11.85 mm Hg). Similarly, as with supine diastolic blood pressure, the global test to assess the efficacy of four doses of valsartan vs placebo was statistically significant (P Ͻ 0.05) with the Dunnett multiple comparison procedure applied. The results of the pairwise comparisons to placebo are given in Table 2 .
Responder rates: Responder rates were 16%, 24%, 33%, 46% and 54% for placebo, valsartan 10 mg, 40 mg, 80 mg and 160 mg, respectively. The results also demonstrated a positive dose response.
Pulse rate: No significant changes from baseline in trough supine pulse or trough standing pulse were seen in any group.
Trough/peak ratios: The trough/peak assessment was based on all 115 patients who had available diastolic blood pressures at all three post-dose time points (hours 2, 4, and 6). The results are presented in Figure 3 .
All trough/peak ratio estimates were у50% for all valsartan dose group and consistently smallest at Hour 4 among the three post-dose time points, indicating: (1) that at least 50% of the peak effect in diastolic blood pressure reduction was preserved at trough; and (2) that the peak effect occurred between 2 to 6 hours (around 4 hours) post-dose. It appeared that two trough/peak ratio estimates (out of 12) were greater than one at the early post-dose time point, Hour 2, which may be explained by random errors in the data, in particular a relatively large mean diastolic blood pressure reduction observed at Hour 2 in the placebo group.
Pharmacokinetics: Only 97 patients had available plasma concentration to be included in the pharmacokinetic assessment. Peak valsartan concentrations were reached at 2-4 h post-dose. Plasma levels of valsartan increased as the dose increased from 10 mg to 160 mg (Table 4) . The mean valsartan concentrations observed were consistent within a given dose after 2 and 4 weeks.
Neurohormones:
The plasma concentration of angiotensin II increased after all doses of valsartan ( Figure 4 ). Trough levels of angiotensin II rose to the highest level after 2 weeks of treatment and then levelled off after 4 weeks. No clear correlation was seen between plasma levels and valsartan dose, although the maximum increase in the level of angiotensin II was seen after 160 mg (Figure 4) .
A correlation was observed between increasing doses of valsartan and plasma renin. As the dose of valsartan increased from 10 mg to 160 mg, plasma renin activity increased (Figure 4) . The maximum level of plasma renin for each dose was seen after 2 weeks and then the levels stabilised after 4 weeks of treatment. Aldosterone concentrations decreased after 4 weeks of treatment with the greatest reductions seen 6 h post-dose, however, there was no clear relationship with increasing doses of valsartan (data not shown).
Tolerability and safety
A total of 41 (33.6%) of the 122 randomised patients reported adverse experiences, regardless of relationship to trial medication. Headache was the most frequently reported adverse experience, highest in placebo (12%) and valsartan 10 mg (8%) groups. There was no dose-related incidence of adverse experiences in the valsartan groups, with 44% of patients complaining of adverse experiences on placebo, 44% on valsartan 10 mg, 36% on valsartan 40 mg, 22% on valsartan 80 mg and 21% on valsartan 160 mg.
Adverse experiences considered trial drug related were of mild intensity (except for one patient with equilibrium dysfunction and headache, considered serious, in the placebo group) and were reported by less patients on valsartan compared with placebototal of four patients (16%) in the placebo group (postural hypotension; severe ataxia; headache; nervousness), two patients (8%) in the valsartan 10 mg group (headache; rash), one patient (4%) in the valsartan 40 mg group (mild peripheral oedema), one patient (4.3%) in the valsartan 80 mg group (dizziness) and one patient (4.2%) in the valsartan 160 mg group (libido decrease). No clinically significant trends for adverse experiences were observed in men or women or in patients of different race.
No trial drug-related cough was reported. For routine laboratory parameters, all mean and median values remained within the normal range with no clinically significant changes in any groups. There were no deaths during the trial.
Patients experiencing significant orthostatic decreases in blood pressure (decrease у10 mm Hg in diastolic blood pressure or у20 mm Hg in systolic blood pressure from supine to standing) totalled two (8%) in the placebo group, four (16%) in the valsartan 10 mg group, three (12%) in the valsartan 40 mg group, three (13%) in the valsartan 80 mg group and four (17%) in the valsartan 160 mg group. Almost all changes were decreases in standing systolic blood pressures, in the range of −22 to −54 mm Hg. The standing diastolic decreases were in the range of −10 to −13 mm Hg. These changes were not accompanied by symptoms in any of the valsartan groups. There was one case of symptomatic orthostatic hypotension on placebo which resolved after 10 minutes.
Conclusions
The results of this trial show valsartan to effectively lower blood pressure in patients with mild-to-moderate hypertension, and demonstrate dose-related antihypertensive efficacy of valsartan.
As the dose of valsartan increased from 10 mg to 160 mg, the magnitude of diastolic and systolic blood pressure lowering was greater. The data show doses of 80 mg OD and above to provide good antihypertensive efficacy. Responder rates followed the same trend, with increasing percentage with increasing doses of valsartan.
The pharmacokinetic assessments showed that plasma valsartan concentrations increased with dose, in agreement with previous data seen in healthy patients. 9 Plasma concentrations of valsartan were similar on Days 14 and 28, indicating that there was no significant accumulation of drug. This is as expected since the half-life of valsartan is 6 h and the dosing interval was 24 h. Maximum pharmacodynamic effect (measured by net effect on MSuDBP) was reached at 2-6 h post dose and, as expected, was later than the maximum plasma concentration of valsartan, which was observed at 2 h. The net effect was consistent for Days 14 and 28 for all valsartan doses, suggesting that patients reach pharmacodynamic steady state for diastolic blood pressure by 2-4 weeks of valsartan therapy. The trough/peak results, showing at least 50% of the peak antihypertensive effect observed at trough, are in keeping with current recommendations for once daily antihyper-tensive agents 15 and support a once-daily dose regimen for valsartan.
Valsartan was well tolerated by all patients during this trial. The overall incidence of adverse experiences for the valsartan treatment groups were equal to or less than the placebo group and showed no dose relationship. The good tolerability profile is in keeping with data reported for other angiotensin receptor antagonists. 6, 16, 17 In summary, the data from this study show valsartan to be an effective antihypertensive agent with clear dose-responsive efficacy.
